Abstract：Objective To explore the application value of the standardized monitoring process of activated coagulation time (ACT) in heparin anticoagulation in patients with extracorporeal membrane oxygenation (ECMO). Methods A total of 46 patients who underwent ECMO treatment in the intensive care unit of our hospital from January 2019 to December 2020 were selected，according to different treatment methods, they were divided into study group (30 cases) and control group (16 cases). The two groups of patients were given heparin during the ECMO process. The control group used the conventional ACT monitoring method, and the study group used the ACT standardized monitoring process on the basis of the control group. The service life of the membrane lung, the probability of successful withdrawal, the survival rate within 3 months, the degree of coagulation of the membrane lung, pump and pipeline, and the degree of unfavorable bleeding between the two groups of patients were compared. Results The service life of the membrane lung in the study group was longer than that in the control group, and the successful weaning rate and survival rate within 3 months were higher than those in the control group, the differences were statistically significant (P＜0.05). The degree of coagulation of the membrane lung, pump and pipeline in the study group were better than those of the control group,the differences were statistically significant (P＜0.05). The degree of bleeding in the study group was better than that of the control group, and the difference was statistically significant (P＜0.05). Conclusion The application of ACT standardized monitoring process to ECMO patients can make heparin achieve the best anticoagulation state, improve the degree of blood coagulation, reduce the occurrence of adverse bleeding, there by effectively increasing the patient′s successful withdrawal rate and survival rate within 3 months, it has a high clinical application value.
京公网安备 11010502046607号